Search Results - "GOPINATHAN, Aarthi"

The Pancreas Cancer Microenvironment by FEIG, Christine, GOPINATHAN, Aarthi, NEESSE, Albrecht, CHAN, Derek S, COOK, Natalie, TUVESON, David A

“…Pancreatic ductal adenocarcinoma (PDA) is a common and lethal malignancy resulting in more than 250,000 deaths per year worldwide. Despite extensive efforts,…”
Get full text

CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response by Biasci, Daniele, Smoragiewicz, Martin, Connell, Claire M., Wang, Zhikai, Gao, Ya, Thaventhiran, James E. D., Basu, Bristi, Magiera, Lukasz, Johnson, T. Isaac, Bax, Lisa, Gopinathan, Aarthi, Isherwood, Christopher, Gallagher, Ferdia A., Pawula, Maria, Hudecova, Irena, Gale, Davina, Rosenfeld, Nitzan, Barmpounakis, Petros, Popa, Elizabeta Cristina, Brais, Rebecca, Godfrey, Edmund, Mirk, Fraz, Richards, Frances M., Fearon, Douglas T., Janowitz, Tobias, Jodrell, Duncan I.

“…Inhibition of the chemokine receptor CXCR4 in combination with blockade of the PD-1/PD-L1 T cell checkpoint induces T cell infiltration and anticancer…”
Get full text

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis by DeNicola, Gina M., Karreth, Florian A., Humpton, Timothy J., Gopinathan, Aarthi, Wei, Cong, Frese, Kristopher, Mangal, Dipti, Yu, Kenneth H., Yeo, Charles J., Calhoun, Eric S., Scrimieri, Francesca, Winter, Jordan M., Hruban, Ralph H., Iacobuzio-Donahue, Christine, Kern, Scott E., Blair, Ian A., Tuveson, David A.

“…Radical role reversal Reactive oxygen species (ROS), such as free radicals, are mutagenic and might therefore be expected to promote tumorigenesis. However,…”
Get full text

CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype by Candido, Juliana B., Morton, Jennifer P., Bailey, Peter, Campbell, Andrew D., Karim, Saadia A., Jamieson, Thomas, Lapienyte, Laura, Gopinathan, Aarthi, Clark, William, McGhee, Ewan J., Wang, Jun, Escorcio-Correia, Monica, Zollinger, Raphael, Roshani, Rozita, Drew, Lisa, Rishi, Loveena, Arkell, Rebecca, Evans, T.R. Jeffry, Nixon, Colin, Jodrell, Duncan I., Wilkinson, Robert W., Biankin, Andrew V., Barry, Simon T., Balkwill, Frances R., Sansom, Owen J.

“…Pancreatic ductal adenocarcinoma (PDAC) is resistant to most therapies including single-agent immunotherapy and has a dense desmoplastic stroma, and most…”
Get full text

GEMMs as preclinical models for testing pancreatic cancer therapies by Gopinathan, Aarthi, Morton, Jennifer P, Jodrell, Duncan I, Sansom, Owen J

“…Pancreatic ductal adenocarcinoma is the most common form of pancreatic tumour, with a very limited survival rate and currently no available disease-modifying…”
Get full text

mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer by Driscoll, David R, Karim, Saadia A, Sano, Makoto, Gay, David M, Jacob, Wright, Yu, Jun, Mizukami, Yusuke, Gopinathan, Aarthi, Jodrell, Duncan I, Evans, T R Jeffry, Bardeesy, Nabeel, Hall, Michael N, Quattrochi, Brian J, Klimstra, David S, Barry, Simon T, Sansom, Owen J, Lewis, Brian C, Morton, Jennifer P

“…mTOR signaling controls several critical cellular functions and is deregulated in many cancers, including pancreatic cancer. To date, most efforts have focused…”
Get full text

Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice by Gopinathan, Aarthi, Denicola, Gina M, Frese, Kristopher K, Cook, Natalie, Karreth, Florian A, Mayerle, Julia, Lerch, Markus M, Reinheckel, Thomas, Tuveson, David A

“…The lysosomal protease cathepsin B is upregulated in human pancreatic ductal adenocarcinoma (PDA) and represents a potential therapeutic target. Loss of…”
Get more information

Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9) by Barlesi, Fabrice, Goldberg, Sarah B., Mann, Helen, Gopinathan, Aarthi, Newton, Michael David, Aggarwal, Charu

“…TPS8610 Background: Based on the findings of the phase 3 PACIFIC trial, durvalumab as consolidation therapy is the standard of care for patients with…”
Get full text

KrasG12D and Smad4/Dpc4 Haploinsufficiency Cooperate to Induce Mucinous Cystic Neoplasms and Invasive Adenocarcinoma of the Pancreas by Izeradjene, Kamel, Combs, Chelsea, Best, Melissa, Gopinathan, Aarthi, Wagner, Amary, Grady, William M., Deng, Chu-Xia, Hruban, Ralph H., Adsay, N. Volkan, Tuveson, David A., Hingorani, Sunil R.

Get full text

Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein-α by Kraman, Matthew, Bambrough, Paul J, Arnold, James N, Roberts, Edward W, Magiera, Lukasz, Jones, James O, Gopinathan, Aarthi, Tuveson, David A, Fearon, Douglas T

“…The stromal microenvironment of tumors, which is a mixture of hematopoietic and mesenchymal cells, suppresses immune control of tumor growth. A stromal cell…”
Get full text

A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma by Cook, Natalie, Basu, Bristi, Smith, Donna-Michelle, Gopinathan, Aarthi, Evans, Jeffry, Steward, William P, Palmer, Daniel, Propper, David, Venugopal, Balaji, Hategan, Mirela, Anthoney, D Alan, Hampson, Lisa V, Nebozhyn, Michael, Tuveson, David, Farmer-Hall, Hayley, Turner, Helen, McLeod, Robert, Halford, Sarah, Jodrell, Duncan

“…Background: The Notch pathway is frequently activated in cancer. Pathway inhibition by γ-secretase inhibitors has been shown to be effective in pre-clinical…”
Get full text

Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma by TUVESON, David A, LIQIN ZHU, HRUBAN, Ralph H, JACKS, Tyler, KONIECZNY, Stephen F, GOPINATHAN, Aarthi, WILLIS, Nicholas A, KACHATRIAN, Leili, GROCHOW, Rebecca, PIN, Christopher L, MITIN, Natalia Y, TAPAROWSKY, Elizabeth J, GIMOTTY, Phyllis A

“…Despite the prevalence of oncogenic Kras mutations in the earliest stages of pancreatic ductal adenocarcinoma, the cellular compartment in which oncogenic Kras…”
Get full text

PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer by Barlesi, Fabrice, Cho, Byoung Chul, Goldberg, Sarah B, Yoh, Kiyotaka, Zimmer Gelatti, Ana Caroline, Mann, Helen, Gopinathan, Aarthi, Bielecka, Zofia Felicja, Newton, Michael, Aggarwal, Charu

“…Evidence from the Phase III PACIFIC trial established durvalumab, a monoclonal antibody (mAb) targeting PD-L1, following concurrent chemoradiotherapy (cCRT) as…”
Get more information

MRI with hyperpolarised [1-13C]pyruvate detects advanced pancreatic preneoplasia prior to invasive disease in a mouse model by Serrao, Eva M, Kettunen, Mikko I, Rodrigues, Tiago B, Dzien, Piotr, Wright, Alan J, Gopinathan, Aarthi, Gallagher, Ferdia A, Lewis, David Y, Frese, Kristopher K, Almeida, Jaime, Howat, William J, Tuveson, David A, Brindle, Kevin M

“…Pancreatic cancer (PCa) is treatable by surgery when detected at an early stage. Non-invasive imaging methods able to detect both established tumours and their…”
Get more information

Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging by Strittmatter, Nicole, Richards, Frances M, Race, Alan M, Ling, Stephanie, Sutton, Daniel, Nilsson, Anna, Wallez, Yann, Barnes, Jennifer, Maglennon, Gareth, Gopinathan, Aarthi, Brais, Rebecca, Wong, Edmond, Serra, Maria Paola, Atkinson, James, Smith, Aaron, Wilson, Joanne, Hamm, Gregory, Johnson, Timothy I, Dunlop, Charles R, Kaistha, Brajesh P, Bunch, Josephine, Sansom, Owen J, Takats, Zoltan, Andrén, Per E, Lau, Alan, Barry, Simon T, Goodwin, Richard J. A, Jodrell, Duncan I

“…Gemcitabine (dFdC) is a common treatment for pancreatic cancer; however, it is thought that treatment may fail because tumor stroma prevents drug distribution…”
Get full text

Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas by Izeradjene, Kamel, Combs, Chelsea, Best, Melissa, Gopinathan, Aarthi, Wagner, Amary, Grady, William M, Deng, Chu-Xia, Hruban, Ralph H, Adsay, N Volkan, Tuveson, David A, Hingorani, Sunil R

“…Oncogenic Kras initiates pancreatic tumorigenesis, while subsequent genetic events shape the resultant disease. We show here that concomitant expression of…”
Get full text

Abstract B54: Genetically engineered mouse-derived allografts (GEDAs): an immunocompetent mouse model of PDAC for the evaluation of novel therapeutic strategies by Mollard, Séverine, Frese, Kristopher K., Gopinathan, Aarthi, Richards, Frances M., Jodrell, Duncan I.

“…Abstract Despite recent advances in the treatment of patients with pancreatic adenocarcinoma (PDAC), survival remains low. Pre-clinical models of human…”
Get full text

Abstract B40: Evaluation of the combination of AZD2014 and olaparib in pancreatic cancer cells by Gopinathan, Aarthi, Richards, Frances M., Cosulich, Sabina, Basu, Bristi, Jodrell, Duncan I.

“…Abstract The PI3K/Akt/mTOR pathway is frequently activated in human pancreatic ductal adenocarcinoma (PDAC) and in mouse models of Kras-driven pancreatic…”
Get full text

Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma by Cook, Natalie, Frese, Kristopher K, Bapiro, Tashinga E, Jacobetz, Michael A, Gopinathan, Aarthi, Miller, Jodi L, Rao, Sudhir S, Demuth, Tim, Howat, William J, Jodrell, Duncan I, Tuveson, David A

“…Pancreatic ductal adenocarcinoma (PDA) is a highly lethal disease that is refractory to medical intervention. Notch pathway antagonism has been shown to…”
Get full text

Abstract 627: Antitumor effect of an oligosaccharide API in a genetically engineered mouse-derived allograft (GEDA) by Rao, Shalini V., Steigedal, Tonje S., Gopinathan, Aarthi, Magnussen, Synnøve N., Strand, Sabina S., Jodrell, Duncan, Richards, Fran, Draget, Kurt I., Nordgård, Catherine T.

“…Abstract The use of oligosaccharides as active pharmaceutical ingredients lags behind that of other biological molecules such as proteins and nucleic acids…”
Get full text